InSite Vision starts late-stage trial of cataract surgery drug

InSite Vision Inc. has started enrolling patients in a Phase III trial of a drug to reduce pain and inflammation after cataract surgery. The Alameda company (OTC BB: INSV) will enroll about 240 patients in the two-arm trial of ISV-303, or BromSite, the company said Tuesday. Results from this first of two late-stage BromSite trials are expected in late 2012 or early 2013.

See the San Francisco Business Times data base of clinical trials by Bay Area drug-development companies.

InSite envisions two drugs before FDA next year

InSite Vision Inc. is hoping for double vision.
The Hayward company, reduced last year to eight employees from a 2008 height of 55, enrolled the first patients in a rare two-for-one late-stage trial in an eyelid inflammation disease that could send two drugs in front of federal regulators within a year.

InSite Vision lands $22M from private placement

Eye drug maker InSite Vision Inc. will use most of the $22.2 million raised from a private placement to fund clinical trials and working capital.
The Alameda company (OCTBB: INSV) will issue 37 million shares of its common stock as well as warrants to buy about 14.8 million additional shares. Those warrants will be exercisable for five years at an exercise price of 75 cents per share.

InSite Vision, Merck, Pfizer sue Sandoz over generic eye drug

Alameda-based InSite Vision said Thursday it joined Merck and Pfizer in suing Sandoz over an antibiotic drug for eye, AzaSite, for which Sandoz is seeking FDA marketing approval.

InSite cataract surgery trial results could target market leader

A once-daily topical anti-inflammatory and anti-pain eye drug from InSite Vision Inc. was superior to a commercially available, higher-dose, twice-a-day version of essentially the same drug for patients undergoing cataract surgery, the company said after looking at early data from a Phase I/II study.
The four-arm, 169-patient study showed that ISV-303, a low-dose nonsteroidal anti-inflammatory drug that uses the active ingredient bromfenac, performed better than ISTA Pharmaceuticals’ Xibrom as well as a placebo, according to Alameda-based InSite.

InSite eyes FDA approval for two-drug study